Xconomy

OCTOBER 5, 2018

But since then its stock price has fallen significantly, dropping below $1 per share multiple times in the past two years, which nearly got the listing booted from the Nasdaq exchange. billion in sales in 2017—said Thursday it had had agreed to buy Senomyx for $1.50 Through a U.S. per share, or.

Pricing 81

Pricing Report Sales Company 81

Xconomy

NOVEMBER 11, 2016

Drug company stocks got a boost with the defeat of Hillary Clinton, a vocal critic of drug prices. Will he take a softer stance on drug prices? But her near doubling of Trump (62 to 33 percent) didn’t translate into support for drug price controls. billion in yearly sales. Now, the U.S. FDA GIVETH AND TAKETH….

Patents 87

Patents Study Pricing Research 87

Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. It was the tweet heard around the biotech world, again.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

AUGUST 19, 2016

. —The FDA last summer approved two new cholesterol fighting drugs known as PCSK9 inhibitors, but so far the market has rejected them, resulting in paltry sales. Everyone is waiting until 2017, when huge studies of the drugs’ ability to prevent heart attacks and strokes start to provide data.

Technical Review 40

Technical Review Patents .Net Study 40